RSV prophylactics for pediatric populations: A product review and meta-analysis of real-world effectiveness.

Hum Vaccin ImmunotherJun 25, 2026 (epub)
Clinical ResearchPediatricsOpen access

Isabela O Oliva, Carlos R Oliveira

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis reviewed the real-world effectiveness of RSV prophylactics in pediatric populations, focusing on nirsevimab and maternal RSVpreF vaccination. The study found that nirsevimab had an 80.9% effectiveness against RSV-associated hospitalization, while maternal vaccination showed 79.1% effectiveness. The analysis included data from 43 observational studies.

Key findings

  • Nirsevimab demonstrated an 80.9% effectiveness against RSV-associated hospitalization.
  • Maternal RSVpreF vaccination showed a 79.1% effectiveness in preventing RSV-related hospitalizations.
  • The review emphasizes the importance of equitable access to these prophylactic strategies.

Why it matters

Understanding the effectiveness of new RSV prophylactics is crucial for clinicians managing pediatric patients, particularly in high-risk groups. These findings can inform clinical decisions and public health strategies to reduce RSV-related morbidity.

Source

PubMed · PMID 42348792Free full text on PubMed Central

Published in Hum Vaccin Immunother. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.